Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in Children With Fragile X Syndrome
NCT01725152Phase 2Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of ganaxolone in Fragile X syndrome (FXS), sponsored by Marinus Pharmaceuticals. Started Nov 2012; status: completed.
02
Drugs
ganaxolone
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01725152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01725152.